OBJECTIVE: To evaluate oral micronized progesterone (OMP) to prevent preterm birth (PTB). METHODS: A randomized, double-blind, placebo-controlled trial of 150 women with at least one PTB who received 100 mg ofOMP or placebo twice a day from recruitment (18-24 weeks) until 36 weeks or delivery. RESULTS:PTB occurred in 29 (39.2%) women in the OMP group (n=74) compared with 44 (59.5%) in the control group (n=74, P=0.002). Mean gestational age at delivery was higher in the OMP group (36.1 vs 34.0 weeks, P<0.001). Fewer preterm births occurred between 28 and 31 weeks plus 6 days in the OMP group (RR 0.20; 95% CI, 0.05-0.73, P<0.001). Neonatal age at delivery (34 vs 32 weeks, P<0.001), birth weight (2400 vs 1890 g, P<0.001), NICU stay (>24 h, P<0.001), and Apgar scores (P<0.001) were more favorable in the OMP group, and fewer neonatal deaths occurred (3 vs 7, P=0.190). CONCLUSION:OMP reduced the risk of PTB between 28 and 31 weeks plus 6 days, NICU admissions, and neonatal morbidity and mortality in high risk patients.
RCT Entities:
OBJECTIVE: To evaluate oral micronized progesterone (OMP) to prevent preterm birth (PTB). METHODS: A randomized, double-blind, placebo-controlled trial of 150 women with at least one PTB who received 100 mg of OMP or placebo twice a day from recruitment (18-24 weeks) until 36 weeks or delivery. RESULTS: PTB occurred in 29 (39.2%) women in the OMP group (n=74) compared with 44 (59.5%) in the control group (n=74, P=0.002). Mean gestational age at delivery was higher in the OMP group (36.1 vs 34.0 weeks, P<0.001). Fewer preterm births occurred between 28 and 31 weeks plus 6 days in the OMP group (RR 0.20; 95% CI, 0.05-0.73, P<0.001). Neonatal age at delivery (34 vs 32 weeks, P<0.001), birth weight (2400 vs 1890 g, P<0.001), NICU stay (>24 h, P<0.001), and Apgar scores (P<0.001) were more favorable in the OMP group, and fewer neonatal deaths occurred (3 vs 7, P=0.190). CONCLUSION:OMP reduced the risk of PTB between 28 and 31 weeks plus 6 days, NICU admissions, and neonatal morbidity and mortality in high risk patients.
Authors: Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield Journal: Acta Obstet Gynecol Scand Date: 2011-06-27 Impact factor: 3.636
Authors: Tracy A Manuck; Yinglei Lai; Paul J Meis; Mitchell P Dombrowski; Baha Sibai; Catherine Y Spong; Dwight J Rouse; Celeste P Durnwald; Steve N Caritis; Ronald J Wapner; Brian M Mercer; Susan M Ramin Journal: Am J Obstet Gynecol Date: 2011-04-08 Impact factor: 8.661
Authors: Rupsa C Boelig; Luigi Della Corte; Sherif Ashoush; David McKenna; Gabriele Saccone; Shalini Rajaram; Vincenzo Berghella Journal: Am J Obstet Gynecol MFM Date: 2019-03-27
Authors: Hannah C Zierden; Rachel L Shapiro; Kevin DeLong; Davell M Carter; Laura M Ensign Journal: Adv Drug Deliv Rev Date: 2021-04-23 Impact factor: 17.873